CA2589895A1 - Leader sequences for directing secretion of polypeptides and methods for production thereof - Google Patents

Leader sequences for directing secretion of polypeptides and methods for production thereof Download PDF

Info

Publication number
CA2589895A1
CA2589895A1 CA002589895A CA2589895A CA2589895A1 CA 2589895 A1 CA2589895 A1 CA 2589895A1 CA 002589895 A CA002589895 A CA 002589895A CA 2589895 A CA2589895 A CA 2589895A CA 2589895 A1 CA2589895 A1 CA 2589895A1
Authority
CA
Canada
Prior art keywords
protein
precursor
seq
homo
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002589895A
Other languages
English (en)
French (fr)
Inventor
Robert Forgan Halenbeck
Elizabeth Bosch
Thomas Linnemann
Ernestine Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2589895A1 publication Critical patent/CA2589895A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002589895A 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof Abandoned CA2589895A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64701305P 2005-01-27 2005-01-27
US60/647,013 2005-01-27
PCT/US2006/002951 WO2006081430A2 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Publications (1)

Publication Number Publication Date
CA2589895A1 true CA2589895A1 (en) 2006-08-03

Family

ID=36741080

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002589895A Abandoned CA2589895A1 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Country Status (9)

Country Link
US (1) US20080286834A1 (enExample)
EP (1) EP1841874B1 (enExample)
JP (2) JP2008528033A (enExample)
AT (1) ATE454455T1 (enExample)
AU (1) AU2006207999A1 (enExample)
CA (1) CA2589895A1 (enExample)
DE (1) DE602006011574D1 (enExample)
DK (1) DK1841874T3 (enExample)
WO (1) WO2006081430A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
JP5376948B2 (ja) 2005-09-13 2013-12-25 ナショナル リサーチ カウンシル オブ カナダ 腫瘍細胞活性を調節する方法及び組成物
US9060961B2 (en) * 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2009056330A1 (en) * 2007-10-31 2009-05-07 Eth Zurich Soluble truncated apom proteins and medical uses thereof
EP2271358B1 (en) * 2008-03-25 2018-11-21 Amarantus Therapeutics, Inc. use of mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
RU2509774C2 (ru) 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
US8470554B2 (en) * 2008-12-22 2013-06-25 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active Dkk
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
US8614183B2 (en) 2009-11-13 2013-12-24 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
WO2011063523A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
AU2011248083B2 (en) 2010-05-04 2015-09-10 Five Prime Therapeutics, Inc. Antibodies that bind CSF1R
US8431532B2 (en) 2010-06-28 2013-04-30 Five Prime Therepeutics, Inc. FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
NZ703786A (en) 2010-11-15 2016-08-26 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
WO2012097238A2 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
HK1208233A1 (en) 2012-05-11 2016-02-26 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
MX2014015041A (es) 2012-06-08 2015-06-17 Shire Human Genetic Therapies Administración pulmonar de arnm a células objetivo no pulmonares.
EP2890398A4 (en) 2012-08-31 2016-03-09 Five Prime Therapeutics Inc METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R)
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
PE20160190A1 (es) 2013-08-01 2016-04-28 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
CN107257806B (zh) 2014-12-22 2021-08-10 戊瑞治疗有限公司 用于治疗pvns的抗csf1r抗体
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
LT3283527T (lt) 2015-04-13 2021-03-25 Five Prime Therapeutics, Inc. Kompleksinė terapija vėžio gydymui
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
EP3448414B1 (en) 2016-04-25 2024-04-17 Five Prime Therapeutics, Inc. Nope for treatment of pathological muscle loss and weakness
TWI781120B (zh) 2016-11-02 2022-10-21 美商永斯醫療股份有限公司 Ｐｄ-１之抗體及其用途
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
US20190330376A1 (en) * 2016-12-29 2019-10-31 Development Center For Biotechnology Peptides derived from kininogen-1 for protein drugs in vivo half-life extensions
WO2018183608A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
EP3634988A4 (en) 2017-06-06 2021-02-24 Kindred Biosciences, Inc. ERYTHROPOIETIN AND SIMILAR COMPOUNDS FOR VETERINARY USE
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Ｌｉｌｒｂ２に対する抗体
AU2019302454A1 (en) 2018-07-09 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to ILT4
WO2020146857A1 (en) * 2019-01-11 2020-07-16 Arbele Limited Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof
WO2021178001A1 (en) * 2020-03-05 2021-09-10 Curie Co. Inc. Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
CN116724051A (zh) 2020-08-10 2023-09-08 上海寻百会生物技术有限公司 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
EP1105508B1 (en) * 1998-08-17 2002-09-04 Europäisches Laboratorium Für Molekularbiologie (Embl) Method for purifying biomolecule or protein complexes
WO2005082934A2 (en) * 2004-02-20 2005-09-09 Five Prime Therapeutics, Inc. Novel apo2l and il-24 polypeptides, polynucleotides, and methods of their use
US20070264277A1 (en) * 2004-07-22 2007-11-15 Dirk Behrens Compositions and Methods of Use for Mgd-Csf in Disease Treatment

Also Published As

Publication number Publication date
WO2006081430A3 (en) 2007-04-05
DK1841874T3 (da) 2010-05-17
DE602006011574D1 (de) 2010-02-25
ATE454455T1 (de) 2010-01-15
EP1841874B1 (en) 2010-01-06
JP2008528033A (ja) 2008-07-31
AU2006207999A1 (en) 2006-08-03
EP1841874A2 (en) 2007-10-10
JP2009131268A (ja) 2009-06-18
WO2006081430A9 (en) 2006-11-30
US20080286834A1 (en) 2008-11-20
WO2006081430A2 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
EP1841874B1 (en) Leader sequences for directing secretion of polypeptides and methods for production thereof
CN112375784B (zh) 制备重组新型冠状病毒Spike蛋白的方法
US8084230B2 (en) Trimerizing polypeptides
WO1999063088A2 (en) Membrane-bound proteins and nucleic acids encoding the same
EP3015475A1 (en) Mammalian cells expressing cytomegalovirus antigens
KR20090125047A (ko) 증대된 단백질 발현 및 정제를 위한 방법 및 조성물
CA2980819C (en) System for the presentation of peptides on the cell surface
WO1996041004A1 (en) Method for discovery of peptide receptor agonists
CN119895043A (zh) 一种转座子系统及其应用
EP0244267A2 (en) Variants of decay accelerating factor (DAF) prepared by recombinant DNA technology
JP2002524103A (ja) 胃ポリペプチドｚｓｉｇ２８
CN118480526A (zh) 一种转座酶、转座子、转座子系统及其应用
JP2003513670A (ja) ジフテリア毒素構築体を用いるスクリーニングのための方法および組成物
CN113645990A (zh) 改良的前列腺凋亡反应-4(par-4)多肽及其生产和使用方法
AU2003284260A1 (en) Production of homotrimeric fusion proteins
WO2018076008A1 (en) Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
RU2230751C2 (ru) Пептид mpi без сигнальной последовательности, днк, его кодирующая, вектор, способ определения способности к секретированию тестируемого пептида, способ выделения кднк
CN104119448A (zh) 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN102766202B (zh) Phf14 c端蛋白、其多克隆抗体及应用
Shang et al. High yield purification of an isoleucine zipper-modified CD95 ligand for efficient cell apoptosis initiation and with biotin or DNA-oligomer binding domain to probe ligand functionalization effects
CN104119446A (zh) 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
HK40041902A (en) Method for preparing a recombinant novel coronavirus spike protein
HK40041902B (en) Method for preparing a recombinant novel coronavirus spike protein
WO2002036760A2 (en) Methods for expressing endogenous genes by restriction enzyme mediated integration
US6946247B1 (en) RNAse probe protection assays in screening for modulators of immunoglobulin germline transcription

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued